News
Zoryve’s regulatory and commercial success, together with pipeline progress, supports Arcutis Biotherapeutics’ positive Q2 ...
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback